Mineralys Therapeutics, Inc. MLYS
As ofNov 20, 2026, 3:44 PM EST
- YTD
- -62.47%
- 1 year
- -67.47%
5D -1.37 (-8.98%)
- Market cap
- 1.21B
- EPS (ttm)
- -4.30
- Shares out
- 88.56M
- Forward P/E
- -5.84
- YTD return
- -62.47%
- 1-year return
- -67.47%
- 50-day average
- 21.72
- 200-day average
- 25.90
- Enterprise value
- 693.92M
- Price / book
- 2.49
- Volume
- 856.59K
- Avg volume
- 1.54M
- Open
- 14.08
- Previous close
- 14.16
- Day's range
- 13.57 – 14.08
- 52-week range
- 13.57 – 44.13
- Beta
- 0.82
- Analysts
- Strong Buy
- Price target
- 43.56 (+219.8%)
- Earnings date
- Mar 11, 2027
Key statistics
- Free cash flow
- -210.65M
- Total cash
- 624.67M
- Total debt
- 98.27M
- Return on equity
- -68.50%
- Short % of float
- 10.39%
Fundamental scorecard
4 of 25 checks passed on MLYS’s reported financials
4of 25 checks passed
- Value 1 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 19.00
- Target (mean)
- 43.56
- Target (high)
- 56.00
- Strong buy0
- Buy9
- Hold2
- Sell0
- Strong sell0
Next earnings
Mar 11, 2027
Expected Mar 11, 2027. Consensus EPS estimate -0.67508.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 11, 2027 | Mar 30, 2027 | -0.65 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | -0.5548 | -0.64 | -0.09 | -15.36% |
| Aug 12, 2026 | Jun 30, 2026 | -0.54857 | -2.85 | -2.30 | -419.53% |
| May 6, 2026 | Mar 31, 2026 | -0.51 | -0.47 | +0.04 | +7.84% |
| Mar 12, 2026 | Dec 31, 2025 | -0.51625 | -0.40 | +0.12 | +22.52% |
| Nov 10, 2025 | Sep 30, 2025 | -0.66 | -0.52 | +0.14 | +21.21% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 12, 2026 | UBS | init | — | Neutral |
| Oct 12, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Apr 27, 2026 | TD Cowen | init | — | Buy |
| Mar 13, 2026 | B of A Securities | main | Buy | Buy |
| Dec 19, 2025 | Stifel | main | Buy | Buy |
| Nov 12, 2025 | HC Wainwright & Co. | main | Buy | Buy |
About Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- mineralystx.com
News
Your note
Sign in to keep a note on MLYS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AKKARAJU SRINIVAS | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Feb 18, 2026 | 5,877,220 |
| CONGLETON JON | Chief Executive Officer | Sale | Jul 12, 2026 | 603,621 |
| FERGUSON JAMES J. III | Officer | Stock Award(Grant) | Aug 9, 2026 | 102,400 |
| KARYDAS DAPHNE | Director | Conversion of Exercise of derivative security | Sep 14, 2026 | 6,200 |
| LEVY ADAM SCOTT | Chief Financial Officer | Stock Award(Grant) | Feb 18, 2026 | 48,538 |
| RA CAPITAL MANAGEMENT, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Mar 29, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Catalys Pacific, LLC | 8.81% | 7,799,518 | 110.44M | Sep 29, 2026 |
| RA Capital Management, L.P. | 8.69% | 7,692,750 | 108.93M | Sep 29, 2026 |
| Blackrock Inc. | 6.97% | 6,172,153 | 87.40M | Sep 29, 2026 |
| Samsara BioCapital, LLC | 6.63% | 5,871,018 | 83.13M | Sep 29, 2026 |
| FMR, LLC | 5.32% | 4,713,195 | 66.74M | Sep 29, 2026 |
| Deerfield Management Company, L.P | 4.47% | 3,958,000 | 56.05M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SmallCap World Fund Inc | 2.83% | 2,502,854 | 35.44M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.22% | 1,968,124 | 27.87M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.79% | 1,584,493 | 22.44M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.66% | 1,468,689 | 20.80M | Sep 29, 2026 |
| Fidelity Select Portfolios-Select Health Care Portfolio | 1.33% | 1,180,000 | 16.71M | Sep 29, 2026 |
| American Century Mutual Funds, Inc.-Small Cap Growth Fund | 1.09% | 962,999 | 13.64M | Sep 29, 2026 |
